Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineEvent-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer

An earlier analysis of this phase 3 trial of neoadjuvant and adjuvant therapy showed that the addition of pembrolizumab to neoadjuvant chemotherapy resulted in a significantly higher percentage of patients with early triple-negative breast cancer having a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery. The trial’s main findings on event-free survival have not been published.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form